<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261533</url>
  </required_header>
  <id_info>
    <org_study_id>VISBOR-61165995002</org_study_id>
    <nct_id>NCT01261533</nct_id>
  </id_info>
  <brief_title>Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment</brief_title>
  <official_title>The Multi-center Exploratory Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GuangZhou WeiShiBo Biotechnology Co., ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GuangZhou WeiShiBo Biotechnology Co., ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility, primary safety and efficacy of
      foldable capsular vitreous body (FCVB) in the treatment of retinal detachment, based on the
      multi-center clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous clinical trial have demonstrated that foldable artificial vitreous body (FCVB),with
      balanced salt solution (BSS) filled in 11 patients during three-months observation,or
      silicone oil filled in 4 patients during a six-month observation respectively, can be
      transplanted into the vitreous body easily, and performances good safety and efficacy in the
      treatment of severe retinal detachment.

      Current multi-center clinical trial was to determine the feasibility, primary safety and
      efficacy of FCVB with silicone oil filled in the treatment of retinal detachment in 120
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete retinal reattach rate at the 52 weeks after implantation of the FCVB</measure>
    <time_frame>52 weeks after implantation of the FCVB</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal reattach rate, Visual function，and Silicone oil change</measure>
    <time_frame>Before surgery, 3days,1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks after FCVB implantation surgery (If patients ask for the delay of removal of FCVB, the patients must received a review every three months)</time_frame>
    <description>visual acuity, intraocular pressure, axial length, ocular inflammatory response, the number of corneal endothelial, emulsification rate of silicone oil, migration of silicone oil droplets into the anterior, chamber, anterior chamber angle and ciliary body change, morphological changes of the ocular and FCVB.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Retinal Detachment</condition>
  <arm_group>
    <arm_group_label>FCVB team</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>foldable capsular vitreous body(FCVB)</intervention_name>
    <description>FCVB with silicone oil inside is tamponaded into the vitreous cavity</description>
    <arm_group_label>FCVB team</arm_group_label>
    <other_name>FCVB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age range from 18 to 65, Refractive error less than ±3D

          2. Corrected visual acuity less than 0.05

          3. ocular axial length is 16 to 25mm

          4. severe retinal detachment that can not be treated by current artificial vitreous body:

               1. Severe unilateral ocular perforating injuries, compounded retinal or choroidal
                  detachments resulted from retinal rupture or retinal choroidal hemorrhage.

               2. Severe unilateral ocular rupture injuries result in retina or choroid defect.

               3. Giant posterior scleral rupture injuries that can not be repaired.

               4. Silicone oil can't be taken out for a long time with incomplete reattachment.

               5. Participants have undergone retinal detachment surgery and silicone oil tamponade
                  twice or more, however, retina is re-detachment after silicone oil removal.

          5. Participants can understand the aim of this clinical trial and sign the informed
             consent form

        Exclusion Criteria:

          1. Participants have a silica gel allergy or scar diathesis

          2. entophthalmia

          3. uveitis

          4. The contralateral eye suffered from intraocular surgery

          5. uncontrollable the other eye diseases

          6. Corrected visual acuity of contralateral eye less than 0.4

          7. Proliferative diabetic retinopathy

          8. the lens of target eye is transparent

          9. Serious heart, lung, liver and kidney dysfunction

         10. pregnancy, preparation for pregnancy during clinical trial and breast-feeding female

         11. drug abuse or alcoholism

         12. participated the other drug or medical devices clinical trial before screening of this
             trial

         13. Any research doctors consider that the condition of participants will hinder the
             clinical trial--Prone to mental stress, loss control of mood, depression etc.

         14. Patient adherence is so poor that study procedures can not be finished
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qianying Gao, MD,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lian Zhou</last_name>
    <phone>020-61165995</phone>
    <email>vesber_zl@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>010-11616669</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>010-65296114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>023-65318301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Huang</last_name>
      <phone>020-87330490</phone>
      <email>gaoketizu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 2nd affiliated hospital of Harbin Medicinal University.</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0451-86662961</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>027-88041911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye and ENT Hospital of FuDan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>021-64377134</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>XiJing Hospital</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>029-3375015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The affiliated Eye Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0577-88068822</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gao Q, Mou S, Ge J, To CH, Hui Y, Liu A, Wang Z, Long C, Tan J. A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve. Eye (Lond). 2008 Mar;22(3):461-8. Epub 2007 May 25.</citation>
    <PMID>17525767</PMID>
  </reference>
  <reference>
    <citation>Gao Q, Chen X, Ge J, Liu Y, Jiang Z, Lin Z, Liu Y. Refractive shifts in four selected artificial vitreous substitutes based on Gullstrand-Emsley and Liou-Brennan schematic eyes. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3529-34. doi: 10.1167/iovs.08-2802. Epub 2009 Mar 5.</citation>
    <PMID>19264881</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Jiang Z, Gao Q, Ge J, Chen J, Cao X, Shen Q, Ma P. Technical standards of a foldable capsular vitreous body in terms of mechanical, optical, and biocompatible properties. Artif Organs. 2010 Oct;34(10):836-45. doi: 10.1111/j.1525-1594.2010.01006.x.</citation>
    <PMID>20618225</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Ke Q, Chen J, Wang Z, Xie Z, Jiang Z, Ge J, Gao Q. Sustained mechanical release of dexamethasone sodium phosphate from a foldable capsular vitreous body. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1636-42. doi: 10.1167/iovs.09-4134. Epub 2009 Oct 15.</citation>
    <PMID>19834025</PMID>
  </reference>
  <reference>
    <citation>Lin X, Ge J, Gao Q, Wang Z, Long C, He L, Liu Y, Jiang Z. Evaluation of the flexibility, efficacy, and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment. Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):374-81. doi: 10.1167/iovs.10-5869.</citation>
    <PMID>20811065</PMID>
  </reference>
  <reference>
    <citation>Zhang R, Wang T, Xie C, Lin X, Jiang Z, Wang Z, Liu Y, Luo Y, Long C, He L, Wang P, Gao Q. Evaluation of supporting role of a foldable capsular vitreous body with magnetic resonance imaging in the treatment of severe retinal detachment in human eyes. Eye (Lond). 2011 Jun;25(6):794-802. doi: 10.1038/eye.2011.61. Epub 2011 Mar 18.</citation>
    <PMID>21423138</PMID>
  </reference>
  <reference>
    <citation>Wang P, Gao Q, Jiang Z, Lin J, Liu Y, Chen J, Zhou L, Li H, Yang Q, Wang T. Biocompatibility and retinal support of a foldable capsular vitreous body injected with saline or silicone oil implanted in rabbit eyes. Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):e67-75. doi: 10.1111/j.1442-9071.2011.02664.x. Epub 2011 Oct 20.</citation>
    <PMID>21883770</PMID>
  </reference>
  <reference>
    <citation>Lin X, Wang Z, Jiang Z, Long C, Liu Y, Wang P, Jin C, Yi C, Gao Q. Preliminary efficacy and safety of a silicone oil-filled foldable capsular vitreous body in the treatment of severe retinal detachment. Retina. 2012 Apr;32(4):729-41. doi: 10.1097/IAE.0b013e31822b1f80.</citation>
    <PMID>22105508</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>May 22, 2013</last_update_submitted>
  <last_update_submitted_qc>May 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitreous body substitute</keyword>
  <keyword>foldable capsular vitreous body</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dissociative Disorders</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

